Resource Library / AMAG Pharmaceuticals, Inc. Studies

studies

AMAG Pharmaceuticals, Inc. Studies

Ciraparantag is in clinical development as a reversal agent for various anticoagulants including non-vitamin K oral anticoagulants (NOACs). Ciraparantag was previously shown to reverse the anticoagulant effects of edoxaban and enoxaparin, as measured by whole blood clotting time (WBCT).

Register to gain access to gated resources.

"*" indicates required fields

Company

This field is for validation purposes and should be left unchanged.

First Name*

Last Name*

Company*

State*

Country

Country

Email*

Phone*

Please only hit the submit button once.

I AGREE*

By submitting this form I agree that Frontage may process my data in the manner described in Frontage’s Privacy Policy.